Innovating Works

IMCYSE SA

Desconocido
CLAIMS: CLinical impact through AI-assisted MS care IMCYSE SA participó en un HORIZON EUROPE: HORIZON-JU-IHI-2022-01-single-stage Multiple sclerosis (MS) is a devastating immune-mediated disorder of the central nervous system. Since there is no cure available yet for MS...
2023-05-15 - 2027-05-31 | Financiado
INNODIA HARVEST: Translational approaches to disease modifying therapy of type 1 diabetes HARVESTing the fruits of... IMCYSE SA participó en un H2020: H2020-JTI-IMI2-2019-19-single-stage Building on the strong foundations of INNODIA, with its unique, Europe-wide clinical and basic research network for the study of type 1 diab...
2020-04-16 - 2024-04-30 | Financiado
INNODIA: Translational approaches to disease modifying therapy of type 1 diabetes an innovative approach tow... IMCYSE SA participó en un H2020: H2020-JTI-IMI2-2014-01-two-stage Preclinical type 1 diabetes (T1D) research has made important advances in recent years, but less progress has been made in translating findi...
2015-12-07 - 2023-10-31 | Financiado
EXALT: Proposal to assess an innovative Immunotherapy based on a thioredox peptide antigen in a Phase I T... IMCYSE SA participó en un FP7: Type-1 diabetes (T1D) is an autoimmune disease in which pancreatic β-cells are gradually destroyed by autoreactive T-cells recognising autoa...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.